New cell therapy targets tough childhood leukemia
NCT ID NCT04678336
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new treatment for children and young adults with acute myeloid leukemia (AML) that returned or didn't respond to standard therapy. The treatment involved taking patients' own immune cells, engineering them to recognize and attack leukemia cells (CART123), and giving them back intravenously. The main goal was to check safety and find the right dose. The study was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat leukemia
- New combo aims to beat High-Risk leukemia and MDS
- Cord blood immune cells tested against tough leukemia
- New targeted therapy shows promise for Tough-to-Treat leukemia
- Supercharged immune cells aim to stop leukemia relapse after transplant
- New chemo regimen shows promise for childhood leukemia